LSTA news

Lisata Therapeutics announced the appointment of Jeffrey Farrow, a veteran CFO, to its Board of Directors effective October 13. The move strengthens the Board during the clinical development of its lead pipeline candidates.

Lisata entered into a definitive merger agreement with Marea Therapeutics to combine via a business combination. This transaction is expected to enable Lisata to become a public company.

The Company amended its merger agreement with Kuva Labs to extend the Outside Date from July 17 to July 21, 2026. This adjustment follows an extension of the time available to consummate the business combination.

Lisata Therapeutics and Kuva Labs amended their merger agreement dated March 6, 2026, revising the offer price to $4.00 per share in cash plus one contingent value right (CVR) per share for future milestone payments. The amendment extends the offer commencement timeline and modifies key merger terms…